Mothers who were enrolled in the Mood, Mother and Infant study will be eligible to
participate in the 6-year follow-up maternal visit. At the time of this visit, mothers will
be randomized to a single 24 IU dose of nasal oxytocin or placebo. Following administration
of the study drug, women will participate in the Trier Social Stress Test (TSST), and blood
samples will be collected to quantify HPA axis reactivity.